520880 港股通创新药ETF
已收盘 02-13 14:59:59
资讯
新帖
简况
【ETF动向】2月10日汇添富国证港股通创新药ETF基金涨3.27%,份额增加1.28亿份
证券之星 · 02-11 08:02
【ETF动向】2月10日汇添富国证港股通创新药ETF基金涨3.27%,份额增加1.28亿份
震撼88.5亿美金!天价创新药BD点火,520880摸高2.75%,港股通医疗ETF(159137)五连阳!机构提示低位机遇
新浪基金 · 02-09
震撼88.5亿美金!天价创新药BD点火,520880摸高2.75%,港股通医疗ETF(159137)五连阳!机构提示低位机遇
信达生物与礼来达成重磅合作,港股通创新药ETF易方达涨1.77%
财闻 · 02-09
信达生物与礼来达成重磅合作,港股通创新药ETF易方达涨1.77%
签下185亿美元超级大单,石药为何反遭抛售?“聪明钱”悄然借道港股通创新药ETF(520880)埋伏
新浪基金 · 02-01
签下185亿美元超级大单,石药为何反遭抛售?“聪明钱”悄然借道港股通创新药ETF(520880)埋伏
新修订《药品管理法实施条例》发布,港股通创新药ETF(520880)放量反弹,亿元级资金提前进场
新浪基金 · 01-28
新修订《药品管理法实施条例》发布,港股通创新药ETF(520880)放量反弹,亿元级资金提前进场
创新药出海BD仍然火爆!港股通创新药ETF(520880)跌1.5%延续高溢价,最新单周吸金2.36亿元
新浪基金 · 01-26
创新药出海BD仍然火爆!港股通创新药ETF(520880)跌1.5%延续高溢价,最新单周吸金2.36亿元
跌够了!港股通创新药ETF(520880)放量反弹,阶段拐点到了?政策放大招,2.38亿资金已进场
新浪基金 · 01-23
跌够了!港股通创新药ETF(520880)放量反弹,阶段拐点到了?政策放大招,2.38亿资金已进场
汇添富基金乐无穹旗下汇添富国证港股通创新药ETF年报最新持仓,重仓石药集团
证券之星 · 01-22
汇添富基金乐无穹旗下汇添富国证港股通创新药ETF年报最新持仓,重仓石药集团
银华基金马君旗下银华国证港股通创新药ETF年报最新持仓,重仓石药集团
证券之星 · 01-21
银华基金马君旗下银华国证港股通创新药ETF年报最新持仓,重仓石药集团
港股通创新药三连跌,什么原因?520880放量跌2.72%溢价高企!机构维持重点推荐
新浪基金 · 01-19
港股通创新药三连跌,什么原因?520880放量跌2.72%溢价高企!机构维持重点推荐
再迎配置窗口?港股通创新药ETF(520880)跌2.7%宽幅溢价!机构:2026年仍重点推荐创新药板块
新浪基金 · 01-19
再迎配置窗口?港股通创新药ETF(520880)跌2.7%宽幅溢价!机构:2026年仍重点推荐创新药板块
【ETF动向】1月13日汇添富国证港股通创新药ETF基金涨0.23%,份额增加2.86亿份
证券之星 · 01-14
【ETF动向】1月13日汇添富国证港股通创新药ETF基金涨0.23%,份额增加2.86亿份
【ETF动向】1月12日汇添富国证港股通创新药ETF基金跌0.75%,份额增加2.46亿份
证券之星 · 01-13
【ETF动向】1月12日汇添富国证港股通创新药ETF基金跌0.75%,份额增加2.46亿份
【ETF动向】1月6日汇添富国证港股通创新药ETF基金涨0.18%,份额增加2.66亿份
证券之星 · 01-07
【ETF动向】1月6日汇添富国证港股通创新药ETF基金涨0.18%,份额增加2.66亿份
乐观BD预期退潮?港股通创新药ETF(520880)创5个半月新低!场内延续宽幅溢价,机构:基本面无虞
新浪基金 · 2025-12-30
乐观BD预期退潮?港股通创新药ETF(520880)创5个半月新低!场内延续宽幅溢价,机构:基本面无虞
跨国药企发起降价潮?港股通创新药逆市走低,520880溢价高企!机构力挺国产创新药:重点关注2026年Q1
新浪基金 · 2025-12-29
跨国药企发起降价潮?港股通创新药逆市走低,520880溢价高企!机构力挺国产创新药:重点关注2026年Q1
三连涨后首度回调,港股通创新药ETF(520880)跌近1%高频溢价!机构:关注“硬创新”+“强出海”创新药资产
新浪基金 · 2025-12-22
三连涨后首度回调,港股通创新药ETF(520880)跌近1%高频溢价!机构:关注“硬创新”+“强出海”创新药资产
午后突发!港股通创新药ETF(520880)跌2.77%创阶段新低,康方生物、百济神州等大权重龙头领跌
新浪基金 · 2025-12-15
午后突发!港股通创新药ETF(520880)跌2.77%创阶段新低,康方生物、百济神州等大权重龙头领跌
重磅官宣,康方生物大涨6.8%!创新药龙头集体提振,高弹性港股通创新药ETF(520880)转涨拉升逾1%
新浪基金 · 2025-12-12
重磅官宣,康方生物大涨6.8%!创新药龙头集体提振,高弹性港股通创新药ETF(520880)转涨拉升逾1%
【ETF动向】12月8日银华国证港股通创新药ETF基金跌1.42%,份额增加8300万份
证券之星 · 2025-12-09
【ETF动向】12月8日银华国证港股通创新药ETF基金跌1.42%,份额增加8300万份
加载更多
公司概况
公司名称:
--
所属市场:
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"520880","market":"SH","secType":"STK","nameCN":"港股通创新药ETF","latestPrice":0.519,"timestamp":1770965999000,"preClose":0.521,"halted":0,"volume":322569900,"delay":0,"changeRate":-0.0038,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.002,"latestTime":"02-13 14:59:59","open":0.518,"high":0.522,"low":0.516,"amount":167000000,"amplitude":0.0115,"askPrice":0.519,"askSize":72606,"bidPrice":0.518,"bidSize":53730,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":0.521,"symbolType":"fund","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":0.573,"lowLimit":0.469,"ibTradeSell":false,"ibTradeBuySell":false,"isCdr":false,"pbRate":0,"committee":-0.110123,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/520880","defaultTab":"news","newsList":[{"id":"2610467060","title":"【ETF动向】2月10日汇添富国证港股通创新药ETF基金涨3.27%,份额增加1.28亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2610467060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610467060?lang=zh_cn&edition=full","pubTime":"2026-02-11 08:02","pubTimestamp":1770768132,"startTime":"0","endTime":"0","summary":"证券之星消息,2月10日,汇添富国证港股通创新药ETF基金(159570)涨3.27%,成交额26.27亿元。当日份额增加了1.28亿份,最新份额为155.55亿份,近20个交易日份额增加5.22亿份。当日资金净流入8.64亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为258.69亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-38.06%,近一个月超额回报为-0.38%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100004724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2610321436","title":"震撼88.5亿美金!天价创新药BD点火,520880摸高2.75%,港股通医疗ETF(159137)五连阳!机构提示低位机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610321436","media":"新浪基金","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610321436?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:36","pubTimestamp":1770636960,"startTime":"0","endTime":"0","summary":"2月9日,港股市场全面反弹,港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单,无意外全天领涨,最高涨至8.55%,收涨7.42%,龙头股大受提振,百济神州涨超3%,石药集团、中国生物制药、三生制药集体跟涨。 100%创新药研发标的——港股通创新药ETF高开后上探2.75%,收涨1.77%成功连阳,一并站上10日均线,全天成交3.81亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-09/doc-inhmfqca5267862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880","BK1574","BK1161","159137","06978","520510","159992"],"gpt_icon":0},{"id":"2610558688","title":"信达生物与礼来达成重磅合作,港股通创新药ETF易方达涨1.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610558688","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610558688?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:44","pubTimestamp":1770605040,"startTime":"0","endTime":"0","summary":"截止2月9日10点23分,上证指数涨1.26%,深证成指涨1.69%,创业板指涨2.08%。光伏设备、影视院线、HJT电池等板块涨幅居前。ETF方面,港股通创新药ETF易方达(159316)涨1.77%,成分股康诺亚- ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"34f23f16691bc3dd0945b028f8bb922f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://fund.10jqka.com.cn/20260209/c674649029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["520880"],"gpt_icon":0},{"id":"2608405007","title":"签下185亿美元超级大单,石药为何反遭抛售?“聪明钱”悄然借道港股通创新药ETF(520880)埋伏","url":"https://stock-news.laohu8.com/highlight/detail?id=2608405007","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608405007?lang=zh_cn&edition=full","pubTime":"2026-02-01 19:37","pubTimestamp":1769945820,"startTime":"0","endTime":"0","summary":"中国创新药出海BD再获里程碑式突破! 1月30日,石药集团宣布已与全球生物制药领导者阿斯利康签订战略研发合作与授权协议,以利用集团专有的缓释给药技术平台及多肽药物AI发现平台,开发创新长效多肽药物。若后续所有研发及销售里程碑均达成,石药集团方面有权获得总计高达185亿美元的款项。其12亿美元的预付款,仅次于此前三生制药与辉瑞就PD-1/VEGF达成的数额。此前10日,520880累获逾2.74亿元资金净申购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-02-01/doc-inhkihyz4934390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0880133367.SGD","LU1328277881.USD","BK1521","01093","LU1993786604.SGD","LU1226287875.USD","LU0501845795.SGD","LU1807302812.USD","IE0008368742.USD","LU1813983027.USD","LU1008478684.HKD","520880","LU1152091168.USD","LU1226288253.USD","LU1226287529.USD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287792.SGD","LU2039709279.SGD","LU0314109678.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1152091754.HKD","LU0067412154.USD","BK1515","IE0008369823.USD","IE00B5MMRT66.SGD","LU1960683339.HKD","LU0315179316.USD","LU1226288170.HKD","LU1951186391.HKD","BK1191","HK0000165453.HKD","IE00B543WZ88.USD","LU0140636845.USD","SG9999004220.SGD","LU0072913022.USD"],"gpt_icon":0},{"id":"2606763233","title":"新修订《药品管理法实施条例》发布,港股通创新药ETF(520880)放量反弹,亿元级资金提前进场","url":"https://stock-news.laohu8.com/highlight/detail?id=2606763233","media":"新浪基金","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606763233?lang=zh_cn&edition=full","pubTime":"2026-01-28 10:52","pubTimestamp":1769568720,"startTime":"0","endTime":"0","summary":"1月28日,港股通创新药板块回暖,龙头股石药集团涨超3%,百济神州、中国生物制药、信达生物集体上涨。 100%创新药研发标的——港股通创新药ETF一度涨逾1.5%,成交快速突破2亿元。近期资金面持续升温,截至昨日,520880近5日吸金1.9亿元,份额升至46.18亿份,再创历史新高。 消息面,1月27日,新修订《药品管理法实施条例》发布,首次为儿童药、罕见病药设立最长7年市场独占期,并强化网售平台责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-01-28/doc-inhivmmh4033981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880"],"gpt_icon":0},{"id":"2606629646","title":"创新药出海BD仍然火爆!港股通创新药ETF(520880)跌1.5%延续高溢价,最新单周吸金2.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606629646","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606629646?lang=zh_cn&edition=full","pubTime":"2026-01-26 13:42","pubTimestamp":1769406120,"startTime":"0","endTime":"0","summary":"1月26日,港股再陷调整,创新药板块再度走低,港股通创新药ETF跌1.5%,场内延续高溢价,显示买盘态度积极。上周,520880累跌3.2%,单周获超2.36亿元资金逢跌吸筹。 成份股方面,龙头股呈普跌态势,石药集团跌3%,康方生物跌近4%,中国生物制药、信达生物跌逾2%。 资金频频逆市增仓,产业方面,年初多个创新药BD交易落地,中国创新药出海的趋势向好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-01-26/doc-inhircpe6485511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","06978","520880","BK1161"],"gpt_icon":0},{"id":"2605474070","title":"跌够了!港股通创新药ETF(520880)放量反弹,阶段拐点到了?政策放大招,2.38亿资金已进场","url":"https://stock-news.laohu8.com/highlight/detail?id=2605474070","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605474070?lang=zh_cn&edition=full","pubTime":"2026-01-23 19:47","pubTimestamp":1769168820,"startTime":"0","endTime":"0","summary":"连跌6日后,港股通创新药今日终于反弹,港股通创新药ETF盘初一度涨超2%,收涨1.53%终结六连阴,放量成交3.48亿元。成份股云顶新耀领涨8.2%,权重股康方生物涨3.5%,石药集团、百济神州均收红。低吸资金逆向布局,截至1月22日,520880周内累获超2.38亿元净申购,最新份额升至45.38亿份新高。 一键投资创新药,认准高弹性T+0利器——港股通创新药ETF及其场外联接基金,标的指数具备三大独特优势,配置价值突出:","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-01-23/doc-inhihwxw0991193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880"],"gpt_icon":0},{"id":"2605395431","title":"汇添富基金乐无穹旗下汇添富国证港股通创新药ETF年报最新持仓,重仓石药集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2605395431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605395431?lang=zh_cn&edition=full","pubTime":"2026-01-22 07:16","pubTimestamp":1769037391,"startTime":"0","endTime":"0","summary":"证券之星消息,1月22日汇添富基金旗下乐无穹管理的汇添富国证港股通创新药交易型开放式指数基金公布年报,近1年净值增长率80.41%。与上一季度相比,该基金前十大重仓股新增康哲药业,亚盛医药-B;并对石药集团增仓9684.6万股,为该基金第一大重仓股;再鼎医药,荣昌生物等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200004452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1993786604.SGD","IE00BZ08YT58.USD","LU0314109678.HKD","LU0501845795.SGD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1328277881.USD","LU1226287875.USD","LU0072913022.USD","LU1226287529.USD","HK0000165453.HKD","BK1515","BK1521","LU0315179316.USD","IE00B031HY20.USD","LU1226287792.SGD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU2039709279.SGD","LU0067412154.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","IE0008368742.USD","01093","LU1807302812.USD","LU1008478684.HKD","LU1152091168.USD","IE0008369823.USD","BK1191","IE00B543WZ88.USD","LU1226288170.HKD","LU1951186391.HKD","520880","LU0326950275.SGD","LU1152091754.HKD","LU1960683339.HKD","LU1813983027.USD"],"gpt_icon":0},{"id":"2605141521","title":"银华基金马君旗下银华国证港股通创新药ETF年报最新持仓,重仓石药集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2605141521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605141521?lang=zh_cn&edition=full","pubTime":"2026-01-21 05:29","pubTimestamp":1768944540,"startTime":"0","endTime":"0","summary":"证券之星消息,1月21日银华基金旗下马君管理的银华国证港股通创新药交易型开放式指数基金公布年报,近1年净值增长率78.86%。与上一季度相比,该基金前十大重仓股新增康哲药业,亚盛医药-B;并对石药集团增仓4022.8万股,为该基金第一大重仓股;再鼎医药,荣昌生物等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100003040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1008478684.HKD","520880","LU0501845795.SGD","LU1807302812.USD","BK1191","HK0000165453.HKD","LU1813983027.USD","IE0008369823.USD","LU1951186391.HKD","LU1226287792.SGD","LU0880133367.SGD","BK1521","LU0072913022.USD","LU0314109678.HKD","LU0140636845.USD","LU0315179316.USD","IE0008368742.USD","LU2039709279.SGD","LU1328277881.USD","IE00B5MMRT66.SGD","LU1152091754.HKD","01093","LU1226287875.USD","IE00B031HY20.USD","LU1993786604.SGD","IE00BZ08YR35.GBP","LU0326950275.SGD","LU1960683339.HKD","IE00B543WZ88.USD","LU1226287529.USD","SG9999004220.SGD","LU1226288253.USD","BK1515","IE00BZ08YT58.USD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","LU0067412154.USD"],"gpt_icon":0},{"id":"2604972138","title":"港股通创新药三连跌,什么原因?520880放量跌2.72%溢价高企!机构维持重点推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2604972138","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604972138?lang=zh_cn&edition=full","pubTime":"2026-01-19 19:37","pubTimestamp":1768822620,"startTime":"0","endTime":"0","summary":"1月19日,港股全天水下运行,恒指收跌0.76%。行业板块方面,医药跌幅较深:创新药产业链全线调整,阿里健康等AI医疗概念多股续跌,汇聚医疗龙头的港股通医疗ETF华宝、创新药含量100%的港股通创新药ETF双双跌逾2%。 港股通创新药ETF收跌2.72%三连阴,连失10日及60日均线,场内放量溢价,成交3.9亿元,环比增逾五成。 【港股通创新药连续回调,什么原因?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-01-19/doc-inhhvwpr1155961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159992","06978","520880","BK1161"],"gpt_icon":0},{"id":"2604900007","title":"再迎配置窗口?港股通创新药ETF(520880)跌2.7%宽幅溢价!机构:2026年仍重点推荐创新药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2604900007","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604900007?lang=zh_cn&edition=full","pubTime":"2026-01-19 14:37","pubTimestamp":1768804620,"startTime":"0","endTime":"0","summary":"1月19日午后,港股通创新药延续弱势,创新药含量100%的港股通创新药ETF跌逾2.7%,场内宽幅溢价,显示买盘态度积极,当前板块或再度行至配置窗口期。 中泰国际发布医药行业2月投资策略:2026年仍重点推荐创新药板块,建议关注2025年的产品销售收入增长确定性强的企业。 公开资料显示,港股通创新药ETF及其场外联接基金被动跟踪恒生港股通创新药精选指数,该指数具备三大独特优势,配置价值突出:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-01-19/doc-inhhvmxv1257268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574","520880"],"gpt_icon":0},{"id":"2603659635","title":"【ETF动向】1月13日汇添富国证港股通创新药ETF基金涨0.23%,份额增加2.86亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603659635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603659635?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:02","pubTimestamp":1768348931,"startTime":"0","endTime":"0","summary":"证券之星消息,1月13日,汇添富国证港股通创新药ETF基金(159570)涨0.23%,成交额34.13亿元。当日份额增加了2.86亿份,最新份额为150.33亿份,近20个交易日份额增加12.11亿份。当日资金净流入7.73亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为263.06亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-39.34%,近一个月超额回报为-2.51%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400005335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2603522757","title":"【ETF动向】1月12日汇添富国证港股通创新药ETF基金跌0.75%,份额增加2.46亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603522757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603522757?lang=zh_cn&edition=full","pubTime":"2026-01-13 08:01","pubTimestamp":1768262506,"startTime":"0","endTime":"0","summary":"证券之星消息,1月12日,汇添富国证港股通创新药ETF基金(159570)跌0.75%,成交额29.79亿元。当日份额增加了2.46亿份,最新份额为147.47亿份,近20个交易日份额增加9.51亿份。当日资金净流入4.56亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为255.32亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-38.82%,近一个月超额回报为-2.43%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300005440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2601841851","title":"【ETF动向】1月6日汇添富国证港股通创新药ETF基金涨0.18%,份额增加2.66亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2601841851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601841851?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:02","pubTimestamp":1767744142,"startTime":"0","endTime":"0","summary":"证券之星消息,1月6日,汇添富国证港股通创新药ETF基金(159570)涨0.18%,成交额20.83亿元。当日份额增加了2.66亿份,最新份额为141.23亿份,近20个交易日份额增加5.29亿份。当日资金净流入6.2亿元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为233.67亿元。汇添富国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2023-12-28)以来超额回报为-36.48%,近一个月超额回报为-2.03%,管理人为汇添富基金公司,基金经理为乐无穹。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700003917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0},{"id":"2595594750","title":"乐观BD预期退潮?港股通创新药ETF(520880)创5个半月新低!场内延续宽幅溢价,机构:基本面无虞","url":"https://stock-news.laohu8.com/highlight/detail?id=2595594750","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595594750?lang=zh_cn&edition=full","pubTime":"2025-12-30 10:39","pubTimestamp":1767062340,"startTime":"0","endTime":"0","summary":"12月30日,港股通创新药板块继续调整,港股通创新药ETF续跌逾1.5%,场内价格创7月11日以来新低!场内延续宽幅,显示买盘资金仍较强势,昨日已有410万元资金逢跌进场。 中邮证券分析称,近期创新药板块仍处于持续回调阶段,其核心仍是资金面主导的此前乐观BD预期的退潮。 公开资料显示,港股通创新药ETF及其场外联接基金被动跟踪恒生港股通创新药精选指数,该指数具备三大独特优势,配置价值突出:","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-30/doc-inhepszw4392943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880"],"gpt_icon":0},{"id":"2595053262","title":"跨国药企发起降价潮?港股通创新药逆市走低,520880溢价高企!机构力挺国产创新药:重点关注2026年Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2595053262","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595053262?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:07","pubTimestamp":1766977620,"startTime":"0","endTime":"0","summary":"12月29日,港股开市走高,恒指飘红,恒科指一度涨超2%。普涨之下,创新药板块意外走低,港股通创新药ETF盘中跌逾1.5%,权重股石药集团跌逾2%,康方生物、中国生物制药等龙头股均跌逾1%。 不过港股通创新药ETF场内持续溢价交易,显示或有低吸资金逢跌吸筹。 消息面,2025年年末,一场由跨国药企诺和诺德与礼来主动发起的降价潮,在政府采购平台、电商平台悄然上演,实际成交价格较半年前近乎“腰斩”。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-29/doc-inhemqas7995635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","520880","BK1574","159992","06978"],"gpt_icon":0},{"id":"2593530101","title":"三连涨后首度回调,港股通创新药ETF(520880)跌近1%高频溢价!机构:关注“硬创新”+“强出海”创新药资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2593530101","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593530101?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:45","pubTimestamp":1766385900,"startTime":"0","endTime":"0","summary":"12月22日,港股通创新药板块三连涨后首度回调,高人气港股通创新药ETF午后一度跌近1%,场内再现高频溢价,显示买盘资金较为活跃。未来,应关注部分优质创新药资产,一是“硬创新”资产,二是具备较强出海潜力的资产。 把握创新药低吸窗口期,首选同类最大港股通创新药ETF及其场外联接基金,标的指数恒生港股通创新药精选指数具备三大独特优势:","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-22/doc-inhcsexm7825049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161","159992","520880"],"gpt_icon":0},{"id":"2591697904","title":"午后突发!港股通创新药ETF(520880)跌2.77%创阶段新低,康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591697904?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后,港股通创新药板块加速下跌,港股通创新药ETF一度跌至2.77%创近5个月新低,龙头股齐挫,康方生物跌超5%,百济神州跌逾6%,中国生物制药、信达生物跌超3%。 阶段新低之际,“抄底”资金或再行动,港股通创新药ETF场内宽幅溢价,显示买盘资金相对强势。 把握港股创新药低吸窗口期,认准同类最大港股通创新药ETF及其场外联接基金,标的指数恒生港股通创新药精选指数具备三大独特优势:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","LU2476274720.SGD","BK1588","LU0307460666.USD","LU0348766576.USD","BK4139","LU0348784397.USD","LU0348827113.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD","LU0417516902.SGD","LU1303224171.USD","688235","BK1161","LU1961090484.USD","BK1500","LU0348783233.USD","ONC","06160","LU1719994722.HKD","LU2328871848.SGD","BK1574","LU1770034418.SGD","LU2399975544.HKD","LU1720050803.USD","LU0561508036.HKD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU1794554557.SGD","LU2476274308.USD","BK0239","IE00BPRC5H50.USD","LU1969619763.USD","LU2488822045.USD","BK4585","LU0348735423.USD","LU1251922891.USD","09926","LU0588546209.SGD","520880","BK4526","LU0348825331.USD","LU0417516571.SGD","LU2778985437.USD"],"gpt_icon":0},{"id":"2590781875","title":"重磅官宣,康方生物大涨6.8%!创新药龙头集体提振,高弹性港股通创新药ETF(520880)转涨拉升逾1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590781875","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590781875?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:37","pubTimestamp":1765521420,"startTime":"0","endTime":"0","summary":"12月12日午后,港股通创新药板块回暖,高弹性港股通创新药ETF翻红后持续拉升,现涨超1%,今日有望终结日线4连阴形态。值得关注的是,本周520880迎来“抄底”资金增仓,累计净申购额超1.3亿元。 成份股方面,权重龙头股康方生物领涨逾6.8%,信达生物涨超2%,百济神州涨逾1%。“同类最大港股通创新药ETF”:截至11月30日,港股通创新药ETF规模21.42亿元,上市以来日均成交4.58亿元,在跟踪同指数的2只ETF中规模最大、流动性最优。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-12/doc-inhapmrm5749076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","LU0348825331.USD","LU1794554557.SGD","LU0348783233.USD","LU0348766576.USD","LU1961090484.USD","LU0561508036.HKD","LU2488822045.USD","LU0348735423.USD","LU0417516571.SGD","LU0417516738.SGD","LU2778985437.USD","LU0540923850.HKD","LU0348784397.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU2476274308.USD","159992","LU2476274720.SGD","BK1574","520880","LU0348767384.USD","LU1720050803.USD","LU0417516902.SGD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","LU2399975544.HKD","09926","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2590362568","title":"【ETF动向】12月8日银华国证港股通创新药ETF基金跌1.42%,份额增加8300万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2590362568","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590362568?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:02","pubTimestamp":1765238525,"startTime":"0","endTime":"0","summary":"证券之星消息,12月8日,银华国证港股通创新药ETF基金(159567)跌1.42%,成交额12.12亿元。当日份额增加了8300万份,最新份额为101.54亿份,近20个交易日份额增加4.79亿份。当日资金净流出9831.73万元(资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的),最新资产净值计算值为84.24亿元。银华国证港股通创新药ETF基金跟踪标的为国证港股通创新药指数,成立(2024-01-03)以来超额回报为-34.53%,近一个月超额回报为-0.17%,管理人为银华基金公司,基金经理为马君。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900003780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["520880"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770987868688,"stockEarnings":[{"period":"1week","weight":0.0296},{"period":"1month","weight":-0.0613},{"period":"3month","weight":-0.1063},{"period":"6month","weight":-0.1795},{"period":"ytd","weight":0.0462}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0011},{"period":"3month","weight":0.036},{"period":"6month","weight":0.1183},{"period":"1year","weight":0.2354},{"period":"ytd","weight":0.0416}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"港股通创新药ETF(520880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供港股通创新药ETF(520880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"港股通创新药ETF,520880,港股通创新药ETF股票,港股通创新药ETF股票老虎,港股通创新药ETF股票老虎国际,港股通创新药ETF行情,港股通创新药ETF股票行情,港股通创新药ETF股价,港股通创新药ETF股市,港股通创新药ETF股票价格,港股通创新药ETF股票交易,港股通创新药ETF股票购买,港股通创新药ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"港股通创新药ETF(520880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供港股通创新药ETF(520880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}